Tiziana Life Sciences Ltd. announced for the first time, quantitative data showing improvement in White Matter Z scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 USD | +0.61% | -5.68% | +48.21% |
Jun. 28 | Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies | MT |
Jun. 28 | Transcript : Tiziana Life Sciences Ltd - Special Call |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+48.21% | 83.75M | |
+18.97% | 44.44B | |
+41.98% | 40.03B | |
-10.06% | 37.68B | |
+31.15% | 31.46B | |
-7.79% | 27.29B | |
+13.32% | 26.29B | |
+43.05% | 13.8B | |
+31.28% | 12.46B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab